Upstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European Respiratory Society Congress
September 09, 2024 08:00 ET
|
Upstream Bio, Inc.
Upstream gives oral presentation of clinical data for verekitug in patients with severe asthma at European Respiratory Society congress
Upstream Bio Presents Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society International Conference
May 22, 2024 11:15 ET
|
Upstream Bio, Inc.
Positive results from a Phase 1 dose ranging study of verekitug (UPB-101) in asthma presented at ATS 2024
Upstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference
May 15, 2024 07:00 ET
|
Upstream Bio, Inc.
Upstream Bio will present clinical data from dose-ranging study of verekitug (UPB-101) in adults with asthma at the American Thoracic Society conference